The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Ian Justl Ellis, a board-certified physician and founder of Voafit, about personalized GLP-1 treatment. Drawing on his experience as both a patient and physician, he explains how medication levels change as weekly doses accumulate, why individual responses can vary, and how gradual adjustments guided by appetite, side effects, nutrition, and objective progress support more personalized care. We also discuss patient monitoring, dose delivery challenges, and the clinical research needed to evaluate this approach at scale. Listen now on all major platforms."The goal is a felt experience that is positive, that is resulting in objective changes."Meet the guest: Dr. Ian Justl Ellis is a board-certified physician and founder and CEO of Voafit. His work focuses on personalized GLP-1 care, precision dosing, and technology that supports individualized medication management. With a background in emergency medicine, fitness, and medical education, Dr. Ellis brings a multidisciplinary perspective to obesity care. Listen to Dr. Ian Justl Ellis on The GLP-1 Podcast Show, available on all major platforms.Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.Liked this one? Don’t stop now. Here’s what we think you’ll love!What you will learn:(00:00) Highlight(01:47) Introduction(02:52) Personal experience with obesity(08:43) Starting semaglutide(18:40) Precision dosing(25:56) A personalized dosing model(38:37) Dose delivery challenges(43:22) Closing thoughtsThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- WiseVAs- ZentrixOS- Zentrix Insights𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms."Semaglutide reduced both total alcohol consumption and the number of heavy drinking days."Meet the guest: Dr. Anders Fink-Jensen is a professor at the University of Copenhagen and a consultant psychiatrist. His research focuses on psychopharmacology, addiction, severe mental illness, and the clinical evaluation of GLP-1 receptor agonists in people with alcohol use disorder. Listen to Dr. Anders Fink-Jensen on The GLP-1 Podcast Show, available on all major platforms.Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.Liked this one? Don’t stop now. Here’s what we think you’ll love!What you will learn:(00:00) Highlight(02:06) Introduction(03:03) Origins of addiction research(07:24) Semaglutide trial design(12:06) Alcohol use outcomes(18:10) Patient selection(23:33) Future clinical research(27:06) Closing thoughtsThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- ZentrixOS- Zentrix Insights- Elevate- WiseVAs𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Michelle Gordon, a physician board-certified in obesity medicine and CEO of Thrive Span Medical, about obesity care for women in midlife. We discuss how GLP-1 therapy fits into long-term disease management, why slower weight reduction, adequate protein, resistance training, hydration, and fiber matter, and how hormonal changes may affect weight, cognition, and metabolic health. Dr. Gordon also explains when bariatric surgery remains appropriate and why obesity should be treated as a complex chronic disease. Listen now on all major platforms."You need the amount of protein to also fuel your muscles, but it has to be coupled with resistance training."Meet the guest: Dr. Michelle Gordon is a physician board-certified in obesity medicine, lifestyle medicine, and general surgery. She is CEO of Thrive Span Medical, a physician-led telehealth clinic focused on midlife weight gain, menopause, and chronic disease. Her clinical work combines obesity medicine, hormone replacement when indicated, evidence-based lifestyle interventions, and personalized long-term care. Listen to Dr. Michelle Gordon on The GLP-1 Podcast Show, available on all major platforms.Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.Liked this one? Don’t stop now. Here’s what we think you’ll love!What you will learn:(00:00) Highlight(02:42) Introduction(06:08) Gaps in women’s health research(11:20) Muscle preservation during weight loss(15:40) Estrogen and cognitive changes(19:39) Midlife metabolism(22:47) Long-term therapy(31:04) Closing thoughtsThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- Elevate- WiseVAs- ZentrixOS- Zentrix Insights𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jon Campbell, Associate Professor of Medicine at Duke University, about the changing science of GIP and glucagon. We examine GIP physiology, glucagon signaling, weight-independent metabolic effects, multi-receptor agonism, and variability in treatment response. Discover how emerging pharmacology could shape more precise obesity treatment. Listen now on all major platforms."GI think it’s going to take a little while, but people are going to come around to this idea that glucagon, particularly when combined with an incretin like GIP or GLP-1, is a really powerful way to improve metabolic disease."Meet the guest: Dr. Jon Campbell is an Associate Professor of Medicine at Duke University. His research examines incretin hormones, pancreatic islet biology, and the cellular mechanisms that regulate glucose metabolism. His work has helped advance understanding of GIP, GLP-1, glucagon, and the signaling pathways that may shape future metabolic therapies. Listen to Dr. Jon Campbell on The GLP-1 Podcast Show, available on all major platforms.Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.What you will learn:(00:00) Highlight(02:11) Introduction(03:18) GIP biology(07:13) Hormone contributions(12:54) Optimized agonists(16:42) Glucagon actions(20:30) Multi-hormone therapies(26:55) Closing thoughtsThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- Zentrix Insights- ZentrixOS- WiseVAs- Elevate𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Ashley Koff, registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot, about weight health in the GLP-1 era. She explains why body composition matters more than total weight, how digestion and hydration shape nutrition outcomes, why protein advice must be personalized, and how clinicians can support more sustainable metabolic health. Listen now on all major platforms."Weight composition, including the type, amount, and location of bone, muscle, fat, and water, provides a more meaningful signal about health than total weight alone."Meet the guest: Dr. Ashley Koff is a registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot: The Personalized System for Optimal Weight Health. She also serves as Nutrition Course Director for the Integrative and Functional Medicine Fellowship at the Susan Samueli Integrative Health Institute. Her work focuses on personalized nutrition, weight health optimization, metabolic health, practitioner education, and helping patients make better, sustainable choices. Listen to Dr. Ashley Koff on The GLP-1 Podcast Show, available on all major platforms.Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.What you will learn:(00:00) Highlight(02:07) Introduction(05:06) Weight health(07:47) Success markers(10:07) Tracking trends(15:31) Functional status(21:57) Nutrition priorities(31:43) Future careThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- WiseVAs- Elevate- Zentrix Insights- ZentrixOS𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, about complication-centric care for Adiposity-Based Chronic Disease. We examine current obesity guidelines, medication selection according to complications, what the key unmet clinical need is in obesity care, and the role of second-generation GLP-1 medications in type 2 diabetes. Listen now on all major platforms."Obesity treatment should focus on improving complications, quality of life, and health, not simply reaching a target amount of weight loss."Meet the guest: Dr. Timothy Garvey is Endowed Professor and University Professor of Medicine at the University of Alabama at Birmingham. An endocrinologist specializing in obesity and type 2 diabetes, he has authored more than 380 publications and helped establish Adiposity-Based Chronic Disease as a diagnostic framework while leading major obesity guidelines. Listen to Dr. W. Timothy Garvey on The GLP-1 Podcast Show, available on all major platforms.Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.What you will learn:(00:00) Highlight(02:14) Introduction(07:17) Clinical guidelines(10:35) Complication care(15:34) Medication selection(20:39) Disease evidence(29:40) Diabetes management(33:22) Closing thoughtsThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- ZentrixOS- Zentrix Insights- Elevate- WiseVAs𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Christopher Kramer, Chief of the Cardiovascular Division at the University of Virginia Health, about how GLP-1 and GIP therapies are reshaping the treatment of obesity-related heart failure. We explore cardiac remodeling, adipose tissue reduction, cardiovascular outcomes, and the mechanisms behind improved patient health. Listen now on all major platforms!"Treatment with tirzepatide reduced heart failure events by approximately fifty percent while helping patients feel better and perform daily activities more comfortably."Meet the guest: Dr. Christopher Kramer earned his A.B. from Harvard and his M.D. from UCSF before completing cardiology training at the University of Pennsylvania. He is the George A. Beller, MD/Lantheus Medical Imaging Distinguished Professor of Cardiovascular Medicine and Chief of the Cardiovascular Division at the University of Virginia Health. His research focuses on cardiovascular magnetic resonance imaging and heart disease. Listen to Dr. Christopher Kramer on The GLP-1 Podcast Show, available on all major platforms.What you will learn:(00:00) Highlight(01:40) Introduction(09:16) Heart failure outcomes(17:55) Cardiac adipose reduction(23:01) Ventricular remodeling(27:42) Weight loss benefits(30:18) Future triple agonists(31:36) Final QuestionsThe GLP-1 Podcast Show is trusted and supported by innovative companies like:- Elevate- WiseVAs- ZentrixOS- Zentrix Insights𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Richard DiMarchi, Distinguished Professor at Indiana University and a pioneer in peptide therapeutics, about the scientific journey behind GLP-1 therapies, multiagonist drug development, and future obesity treatments. We explore glucagon, GIP, triple agonists, and emerging innovations shaping metabolic medicine. Listen now on all major platforms!"For decades, glucagon was viewed primarily as a hormone that raises blood glucose. Research later revealed that glucagon could also promote weight reduction and improve liver metabolism when balanced appropriately with GLP-1 activity."Meet the guest: Dr. Richard DiMarchi is a Distinguished Professor at Indiana University and a recognized leader in peptide therapeutics, diabetes research, and obesity medicine. His work contributed to major advances in insulin, glucagon, and multiagonist therapies, while also helping establish several biotechnology companies. Dr. DiMarchi continues to advance innovation in the treatment of metabolic diseases through research and translational science. Listen to Dr. Richard DiMarchi on The GLP-1 Podcast Show, available on all major platforms.What you will learn:(00:00) Highlight(01:19) Introduction(05:31) GLP-1 evolution(09:16) Multiagonist design(15:46) Glucagon controversy(17:42) GIP role(24:32) Future treatments(30:13) Final Questions𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast ShowYouTube: The GLP-1 Podcast ShowFacebook: The GLP-1 Podcast ShowTikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Sandra Christensen, obesity medicine specialist and founder of Integrative Medical Weight Management. We examine how GLP-1 therapies impact body composition beyond total weight loss. Dr. Christensen explores fat-free mass reduction, muscle and bone considerations, and clinical risks. She also addresses nutrition strategies, resistance training, and the importance of structured monitoring and personalized care. Listen now on all major platforms!"When evaluating weight reduction outcomes, it is essential to distinguish between fat mass and fat-free mass, because each component has different physiological roles and clinical implications."Meet the guest: Dr. Sandra Christensen is an obesity medicine specialist and founder of Integrative Medical Weight Management in Seattle. She holds advanced certification in obesity medicine and serves as a trustee for the Obesity Medicine Association and president of the Washington Obesity Society. Her work focuses on clinical strategies, patient care, and education in obesity treatment. Learn more from Dr. Sandra Christensen on The GLP-1 Podcast Show, available on all major platforms.What you will learn:(00:00) Highlight(01:07) Introduction(02:34) Body composition(04:09) Fat-free mass(07:46) Protein strategies(12:08) Resistance training(14:51) Monitoring tools(25:47) Final Questions𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jason Itri, Founder of Longevity Health Clinic, about how GLP-1 therapies extend beyond weight loss into cardiometabolic optimization. We examine microdosing strategies, insulin resistance, inflammation pathways, and sustainable habit formation through precision prescribing. Dr. Itri highlights practical clinical applications for long-term metabolic health. Listen now on all major platforms!"Lower dose GLP-1 strategies can improve control over dietary habits by reducing impulsive food decisions and supporting consistent behavioral patterns over extended periods."Meet the guest: Dr. Jason Itri is a physician and the founder of Longevity Health Clinic in Virginia, specializing in cardiometabolic health, hormone optimization, and GLP-1 therapies. His work integrates biomarker testing with root-cause physiology to improve metabolic outcomes and reduce long-term disease risk. His clinical focus aligns with advancing precision approaches in obesity medicine and metabolic care. What you will learn:(00:00) Highlight(01:08) Introduction(05:09) Microdosing strategy(07:27) Habit control(15:11) Risk markers(17:11) Insulin resistance(29:10) Muscle loss(32:20) Final Questions𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The GLP-1 Podcast ShowInstagram: The GLP-1 Podcast ShowLinkedIn: The GLP-1 Podcast Show